Accropeutics has fostered a robust portfolio of innovative compounds spanning from lead optimization to clinical development.
AC-101 (RIPK2 inhibitor)
Completed Phase I clinical studies in Australia and China. Outstanding safety and PK/PD profiles achieved,currently undergoing a Phase Ib trial in Ulcerative Colitis (UC) patients in China,obtained FDA clearance for a phase II MRCT study for the treatment of IBD patients.
AC-201 (a selective TYK2/JAK1 pseudo kinase inhibitor)
"Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, completed Phase I study in Australia and China, completed a phase II clinical trial for patients with moderate to severe plaque psoriasis in China,granted to Fosun Pharma exclusive rights in Mainland China, Hong Kong, and Macau.
AC-003 (RIPK1 inhibitor)
completed Phase I clinical trials in China and the United States,currently undergoing a Phase Ib clinical trial in aGVHD patients in China,obtained Orphan Drug Designation (ODD) from the FDA.
The Company has multiple compounds in the PCC and preclinical research stages. The Company owns more than 20 patents issued in major markets including the US, the EU, China, Japan, and Korea.
Dr. Henri Nico Doods was Senior Vice President of Boehringer Ingelheim and Global Head of Boehringer Ingelheim Research Beyond Border.
Dr. Doods has nearly 30 years of experience in pharmaceutical research and development, covering cardiovascular, pain, obesity, neurological, respiratory and other fields. He published more than 135 papers, and advanced more than 15 compounds into clinical development, including nintedanib (Ofev), the standard of care for the treatment of IPF. He received a Ph.D. degree is from University of Amsterdam.
We entered into an exclusive license agreement with Fosun Pharma for AC-101 for the rights in Mainland China, Hong Kong, and Macau.
AC-201 completes Phase ll clinical trial in China (PsO)
Series B+ Financing
AC-101 First in Patient in Phase Ib for UC in China
AC-101 MRCT Phase II for UC was Approved by FDA
AC-201 Phase II clinical trial for NIU was approved by NMPA
AC-201 First in Patient in China for Phase II in Psoriasis
AC-003 First in Patient in China for Phase Ib in aGVHD
AC-101 clinical trial was approved (HREC)
AC-101 first in human in AUS
AC-003 clinical trial for GVHD was approved (NMPA)
AC-101 IND Approval (NMPA)
AC-201 first in human in AUS
AC-201 IND Approval (NMPA)
AC-201 first in human in China
AC-003 has been granted ODD by the FDA
AC-003 first in human in the US
AC-003 IND Approval (NMPA)
AC-003 first in human in China
Series B Financing
AC-003 IND Approval (FDA)
Series A Financing
Found Accro Bioscience (Suzhou) Limited
For investor relations related matters, please contact us at info@accropeutics.com
